Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

被引：7
|
作者：
Gutman, Jonathan A.
Winters, Amanda
Amaya, Maria L.
McMahon, Christine M.
Schowinsky, Jeffrey
Abbott, Diana
Hammes, Andrew
Pei, Shanshan
Stevens, Brett M.
Jordan, Craig T.
Smith, Clayton
Pollyea, Daniel A.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136120
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
    DiNardo, Courtney D.
    Pratz, Keith
    Pullarkat, Vinod
    Jonas, Brian A.
    Arellano, Martha
    Becker, Pamela S.
    Frankfurt, Olga
    Konopleva, Marina
    Wei, Andrew H.
    Kantarjian, Hagop M.
    Xu, Tu
    Hong, Wan-Jen
    Chyla, Brenda
    Potluri, Jalaja
    Pollyea, Daniel A.
    Letai, Anthony
    BLOOD, 2019, 133 (01) : 7 - 17
  • [22] Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Pratz, Keith
    Potluri, Jalaja
    Pullarkat, Vinod
    Jonas, Brian A.
    Wei, Andrew H.
    Becker, Pamela S.
    Frankfurt, Olga
    Xu, Tu
    Hong, Wan-Jen
    Chyla, Brenda
    Pollyea, Daniel A.
    Letai, Anthony
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S201 - S201
  • [23] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Maximilian Fleischmann
    Sebastian Scholl
    Jochen J. Frietsch
    Inken Hilgendorf
    Karin Schrenk
    Jakob Hammersen
    Florian Prims
    Christian Thiede
    Andreas Hochhaus
    Ulf Schnetzke
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
  • [24] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
    Jonas, Brian A.
    Wei, Andrew H.
    Recher, Christian
    DiNardo, Courtney D.
    Jang, Jun-Ho
    Pratz, Keith
    Panayiotidis, Panayiotis
    Montesinos, Pau
    Yeh, Su-Peng
    Ivanov, Vladimir
    Fiedler, Walter
    Yamauchi, Takahiro
    Duan, Yinghui
    Mendes, Wellington
    Potluri, Jalaja
    Tews, Bjorn
    Ofran, Yishai
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
  • [25] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Fleischmann, Maximilian
    Scholl, Sebastian
    Frietsch, Jochen J.
    Hilgendorf, Inken
    Schrenk, Karin
    Hammersen, Jakob
    Prims, Florian
    Thiede, Christian
    Hochhaus, Andreas
    Schnetzke, Ulf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
  • [26] Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
    Cui, Jingying
    Chen, Xuexing
    Li, Chunfang
    Yan, Qiong
    Yuan, Guolin
    HEMATOLOGY, 2024, 29 (01)
  • [27] DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS
    Zannoni, L.
    Forte, D.
    Sartor, C.
    Cristiano, G.
    Nanni, J.
    Parisi, S.
    Zingarelli, F.
    Bandini, L.
    Testoni, N.
    Ottaviani, E.
    Paolini, S.
    Papayannidis, C.
    Cavo, M.
    Rutella, S.
    Curti, A.
    HAEMATOLOGICA, 2024, 109 : 74 - 75
  • [28] Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
    Borate, Uma
    Huang, Ying
    Li Welkie, Rina
    Swords, Ronan T.
    Traer, Elie
    Stein, Eytan M.
    Lin, Tara L.
    Madanat, Yazan F.
    Patel, Prapti A.
    Collins, Robert H.
    Baer, Maria R.
    Duong, Vu H.
    Blum, William
    Arellano, Martha L.
    Stock, Wendy
    Odenike, Olatoyosi
    Redner, Robert L.
    Kovacsovics, Tibor J.
    Deininger, Michael W.
    Zeidner, Joshua F.
    Olin, Rebecca
    Smith, Catherine C.
    Foran, James M.
    Schiller, Gary J.
    Curran, Emily K.
    Koenig, Kristin L.
    Heerema, Nyla A.
    Chen, Timothy
    Martycz, Molly
    Stefanos, Mona
    Marcus, Sonja Gullen
    Druker, Brian J.
    Levine, Ross L.
    Burd, Amy
    Rossenber, Leohard
    Yocum, Ashley Owen
    Mims, Alice
    Byrd, John C.
    BLOOD, 2024, 144 : 4324 - 4326
  • [29] Risk Stratification of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
    Gardeney, Helene
    Diaz, Jose Miguel Torregrosa
    Basle, Caroline
    Cayssials, Emilie
    Bouyer, Sabrina
    Moya, Niels
    Gruchet, Cecile
    Sabirou, Florence
    Bobin, Arthur
    Levy, Anthony
    Nsiala, Laly
    Cailly, Laura
    Vonfeld, Mathilde
    Desmier, Deborah
    Leleu, Xavier
    Hernanz, Maria Pilar Gallego
    BLOOD, 2021, 138
  • [30] Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective
    Pratz, Keith W.
    Chai, Xinglei
    Xie, Jipan
    Yin, Lei
    Nie, Xiaoyu
    Montez, Melissa
    Iantuono, Erica
    Downs, Lisa
    Ma, Esprit
    BLOOD, 2021, 138
12345